Skip to main content

Advertisement

Table 3 Univariate and multivariate Cox proportional hazards analysis of factors influencing 5-year overall survival for patients who underwent FOLFOX/CapeOX chemotherapy

From: Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

Variables Univariate analysis Multivariate analysis*
HR 95% CI P HR 95% CI P
Gender    0.092    
 Male 1      
 Female 0.845 0.695–1.028     
Age at diagnosis, years    0.003    0.007
 66–70 1    1   
 71–75 1.122 0.872–1.443   1.149 0.888–1.486  
 76–80 1.286 0.994–1.665   1.293 0.991–1.688  
  > 80 1.812 1.305–2.517   1.816 1.285–2.566  
Race    0.206    
 White 1      
 Black 1.028 0.719–1.469     
 Asian 1.156 0.677–1.972     
 Other 0.502 0.259–0.973     
Marital status    0.167    
 Single+Separated 1      
 Married 1.036 0.696–1.543     
 Divorced+Widowed 1.318 0.869–1.999     
 Other 1.066 0.540–2.104     
Residence location    0.329    
 Big Metro 1      
 Metro or Urban 1.071 0.865–1.327     
 Less Urban or Rural 1.252 0.929–1.686     
Median household income    0.007    0.497
 1st quartile 1    1   
 2nd quartile 0.962 0.733–1.261   1.021 0.755–1.380  
 3rd quartile 0.745 0.561–0.989   0.814 0.575–1.152  
 4th quartile 0.620 0.465–0.826   0.792 0.529–1.186  
 Unknown 0.800 0.496–1.291   0.947 0.514–1.743  
Level of education    0.006    0.263
 1st quartile 1    1   
 2nd quartile 1.524 1.117–2.079   1.371 0.979–1.920  
 3rd quartile 1.552 1.147–2.100   1.379 0.960–1.982  
 4th quartile 1.744 1.298–2.343   1.289 0.854–1.947  
 Unknown 1.417 0.863–2.327   N/Aa N/Aa  
Year of diagnosis    0.398    
 2001–2004 1      
 2005–2008 0. 897 0.697–1.154     
Primary tumor site    0.150    
 right-sided colon 1      
 left-sided colon 0.878 0.711–1.084     
 unknown 1.602 0.824–3.114     
Histologic grade    < 0.001    0.022
 Well 1    1   
 Moderate 1.170 0.724–1.892   1.015 0.623–1.653  
 Poor+Undifferentiated 1.973 1.211–3.215   1.407 0.856–2.315  
 Unknown 1.376 0.598–3.165   0.987 0.422–2.309  
Histologic type    0.008    0.148
 Adenocarcinoma 1    1   
 Mucinous carcinoma 1.491 1.146–1.940   1.306 0.997–1.712  
 Signet-ring cell carcinoma 1.467 0.728–2.959   1.147 0.556–2.366  
pT category    < 0.001    < 0.001
 pT1 1    1   
 pT2 1.374 0.499–3.780   1.472 0.531–4.080  
 pT3 3.645 1.506–8.823   2.730 1.118–6.667  
 pT4a 6.221 2.494–15.521   5.077 2.014–12.801  
 pT4b 7.165 2.766–18.559   4.350 1.656–11.424  
pN category    < 0.001    < 0.001
 pN1a 1    1   
 pN1b 1.581 1.172–2.132   1.475 1.090–1.996  
 pN2a 2.301 1.691–3.132   1.970 1.440–2.696  
 pN2b 4.310 3.195–5.814   3.408 2.497–4.650  
Preoperative intestinal obstruction    < 0.001    0.055
 No 1    1   
 Yes 1.680 1.340–2.106   1.258 0.995–1.590  
Preoperative intestinal perforation    0. 165    
 No 1      
 Yes 1.770 0.790–3.966     
HCC risk score    < 0.001    < 0.001
 1st quartile 1    1   
 2nd quartile 0.936 0.683–1.283   1.129 0.816–1.561  
 3rd quartile 1.033 0.754–1.415   1.273 0.918–1.765  
 4th quartile 1.994 1.469–2.705   2.197 1.592–3.033  
Number of examined lymph node    0.382    
  ≥ 12 1      
  < 12 0.906 0.727–1.130     
Postoperative radiotherapy    0.055    
 No 1      
 Yes 1.850 0.988–3.467     
Timing to AC    < 0.001    < 0.001
  ≤ 4 weeks 1    1   
 5–8 weeks 1.028 0.635–1.663   1.009 0.619–1.644 0.971
 9–12 weeks 1.665 1.012–2.739   1.640 0.990–2.717 0.055
 13–16 weeks 1.671 0.935–2.988   1.422 0.788–2.566 0.243
  ≥ 17 weeks 3.144 1.731–5.710   2.482 1.354–4.549 0.003
  1. Abbreviation FOLFOX/CapeOX 5-FU/capecitabine plus oxaliplatin, HR Hazard ratio, CI Confidence interval, HCC Hierarchical Condition Categories, AC Adjuvant chemotherapy
  2. *Only variables with a p < 0.05 in the univariate analysis were included in the multivariate analysis
  3. aunavailable because of colinearity with the variable of Median household income